Firebrick Pharma Limited (ASX: FRE) - Share Price
Current share price for FRE : $0.030 0.002 (6.25%)+
Firebrick Pharma Limited (FRE), an ASX-listed company, is developing and commercialising novel formulations and uses of povidone iodine (PVP-I). The Company has developed and manufactured Nasodine Nasal Spray (0.5% PVP-I), which so far has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines.
FRE General Information +
| ASX Code | FRE |
| Website | http://firebrickpharma.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 8 |
| FRE Share Price | $0.030 |
| Day High | $0.032 |
| Day Low | $0.028 |
| Last Close | $0.032 |
| FRE Share Price Movement | $0.00 ( 6.25% ) |
Prices as at 16:25, 29 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Firebrick Pharma Limited (FRE) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Firebrick Pharma Limited (FRE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Firebrick Pharma Limited (FRE) price-sensitive announcements
FRE - March 2026 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Limited's March 2026 Quarterly Activity Report highlights several key dev
Firebrick Pharma Limited (FRE)
21 Apr 2026 | 4:50 PM
21 Apr 2026 | 4:50 PM
FRE - Firebrick Secures $1.5 million via Placement
Firebrick Pharma Limited, trading on the ASX as FRE, announced it has secured firm commitm
Firebrick Pharma Limited (FRE)
31 Mar 2026 | 9:12 AM
31 Mar 2026 | 9:12 AM
FRE - Trading Halt
On 27 March 2026, Firebrick Pharma Limited (ASX: FRE) requested a trading halt for its sec
Firebrick Pharma Limited (FRE)
27 Mar 2026 | 9:17 AM
27 Mar 2026 | 9:17 AM
FRE - Registration Agreement and Approval of Nasodine in Indonesia
Firebrick Pharma Limited has secured its first regulatory approval for Nasodine Nasal Spra
Firebrick Pharma Limited (FRE)
27 Mar 2026 | 8:55 AM
27 Mar 2026 | 8:55 AM
Firebrick Pharma Limited (FRE) Recent ASX Announcements
FRE Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$2.63 | -$1.30 | 89.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.18 | -$0.70 | -83.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$6.80 | -$4.00 | 22.70% | 0.00 | 0.00 | 0.00% | 0.0% |
FRE Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $761M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Firebrick Pharma Limited (FRE) | $9M | 0.8939 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,618M | -0.7857 | 0.0743 | 1.2000 | 54.8346 | 51.0400 | 23.2000 | 0.00% | 0.00% | 0.00% |
FRE Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.64 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.66 |
| Sector | 0.42 | 26.20 | 2.41 | 2.34 |
FRE Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Peter Laurence Molloy | Founder, Chief Executive Officer, Executive Chairman, Executive Director | 12 Apr 2012 |
| Dr Stephen Francis Goodall | Founder, Chief Operating Officer, Executive Director | 12 Apr 2012 |
| Mr Rick Legleiter | Non-Executive Director | 1 Aug 2025 |
| Mr Al Moghaddam | Non-Executive Director | 1 Mar 2026 |
Firebrick Pharma Limited (FRE) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 20 May 2026 | GOODALL, Stephen | Buy | Indirect Shares | 110,000 | $0.046 | $5,060.000 |
| 20 May 2026 | MOLLOY, Peter | Buy | Indirect Shares | 245,000 | $0.040 | $9,856.020 |
| 10 Oct 2024 | MOLLOY, Peter | Buy | Indirect Shares | 454,545 | $0.055 | $25,000.000 |
See all changes in directors' interest & trades for Firebrick Pharma Limited (FRE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
FRE Management
| Name | Position |
|---|---|
| Stephen Buckley | Company Secretary |
FRE Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Firebrick Pharma Limited (FRE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 31,811,017 (14.35%) | Peter Laurence Molloy |
| 31,038,290 (14%) | Stephen Francis Goodall |
| 24,600,000 (12.60%) | GZ Family Holdings Pty Ltd |
| 11,578,947 (5.22%) | Pharma Nutria N.A Inc |
FRE Calendar of Events
| Date | Event |
|---|---|
| 23 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
